BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31489457)

  • 1. Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma.
    Kim N; Chang JS; Wee CW; Kim IA; Chang JH; Lee HS; Kim SH; Kang SG; Kim EH; Yoon HI; Kim JW; Hong CK; Cho J; Kim E; Kim TM; Kim YJ; Park CK; Kim JW; Kim CY; Choi SH; Kim JH; Park SH; Choe G; Lee ST; Kim IH; Suh CO
    Strahlenther Onkol; 2020 Jan; 196(1):58-69. PubMed ID: 31489457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
    Woo P; Ho J; Lam S; Ma E; Chan D; Wong WK; Mak C; Lee M; Wong ST; Chan KY; Poon WS
    World Neurosurg; 2018 Jul; 115():e375-e385. PubMed ID: 29678708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    Gittleman H; Lim D; Kattan MW; Chakravarti A; Gilbert MR; Lassman AB; Lo SS; Machtay M; Sloan AE; Sulman EP; Tian D; Vogelbaum MA; Wang TJC; Penas-Prado M; Youssef E; Blumenthal DT; Zhang P; Mehta MP; Barnholtz-Sloan JS
    Neuro Oncol; 2017 May; 19(5):669-677. PubMed ID: 28453749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
    Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
    J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.
    Topkan E; Selek U; Ozdemir Y; Yildirim BA; Guler OC; Ciner F; Mertsoylu H; Tufan K
    J Neurooncol; 2018 Sep; 139(2):411-419. PubMed ID: 29696530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
    Patil N; Somasundaram E; Waite KA; Lathia JD; Machtay M; Gilbert MR; Connor JR; Rubin JB; Berens ME; Buerki RA; Choi S; Sloan AE; Penas-Prado M; Ashby LS; Blumenthal DT; Werner-Wasik M; Hunter GK; Flickinger JC; Wendland MM; Panet-Raymond V; Robins HI; Pugh SL; Mehta MP; Barnholtz-Sloan JS
    J Neurooncol; 2021 Dec; 155(3):363-372. PubMed ID: 34761331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
    Guler OC; Yıldırım BA; Önal C; Topkan E
    Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of patterns of care, prognostic factors, and use of radiotherapy-temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study.
    Fabbro-Peray P; Zouaoui S; Darlix A; Fabbro M; Pallud J; Rigau V; Mathieu-Daude H; Bessaoud F; Bauchet F; Riondel A; Sorbets E; Charissoux M; Amelot A; Mandonnet E; Figarella-Branger D; Duffau H; Tretarre B; Taillandier L; Bauchet L
    J Neurooncol; 2019 Mar; 142(1):91-101. PubMed ID: 30523606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
    Joo JD; Kim H; Kim YH; Han JH; Kim CY
    J Korean Med Sci; 2015 Nov; 30(11):1597-603. PubMed ID: 26539003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
    Younis SG; Khedr RA; El-Shorbagy SH
    J Egypt Natl Canc Inst; 2016 Mar; 28(1):23-30. PubMed ID: 26682634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
    Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
    Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study.
    Kudulaiti N; Zhou Z; Luo C; Zhang J; Zhu F; Wu J
    BMC Surg; 2021 May; 21(1):238. PubMed ID: 33957923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
    Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
    J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
    Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y
    Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma.
    Ney DE; Carlson JA; Damek DM; Gaspar LE; Kavanagh BD; Kleinschmidt-DeMasters BK; Waziri AE; Lillehei KO; Reddy K; Chen C
    J Neurooncol; 2015 Mar; 122(1):135-43. PubMed ID: 25524817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology).
    Lombardi G; Pace A; Pasqualetti F; Rizzato S; Faedi M; Anghileri E; Nicolotto E; Bazzoli E; Bellu L; Villani V; Fabi A; Ferrazza P; Gurrieri L; Dall'Agata M; Eoli M; Della Puppa A; Pambuku A; D'Avella D; Berti F; Rudà R; Zagonel V
    J Neurooncol; 2015 Nov; 125(2):359-67. PubMed ID: 26423801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.